Kate Gross was just 36 years old when she died of cancer. Researchers at Cambridge – including her husband – are trying to ensure that others receive their diagnoses early enough to stop their cancer.
Cambridge-based start-up company Bicycle Therapeutics has recently raised £40 million from a range of investors to bring its cancer drug candidates to clinical trials.
Study identifies hundreds of genes that influence timing of puberty and alter risk of several cancers24 Apr 2017
The largest genomic analysis of puberty timing in men and women conducted to date has identified 389 genetic signals associated with puberty timing, four times the number that were previously known.
A new campaign is warning people that burning some food, such as toast, is a potential cancer risk. Here, the evidence for this claim is explored by David Spiegelhalter, Professor of the Public Understanding of Risk at the new Winton Centre for Risk and Evidence Communication.
A small molecule that can turn short-lived ‘killer T-cells’ into long-lived, renewable cells that can last in the body for a longer period of time, activating when necessary to destroy tumour cells, could help make cell-based immunotherapy a realistic prospect to treat cancer.
Cambridge spin-out Carrick Therapeutics raises $95 million in funding, representing the largest-ever early stage investment in a UK university spin-out company.
Researchers have identified the role that a four-stranded version of DNA may play in the role of cancer progression, and suggest that it may be used to develop new targeted cancer therapies.